KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Common Equity (2016 - 2025)

Neogenomics' Common Equity history spans 16 years, with the latest figure at $836.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 7.29% year-over-year to $836.6 million; the TTM value through Dec 2025 reached $836.6 million, down 7.29%, while the annual FY2025 figure was $836.6 million, 7.29% down from the prior year.
  • Common Equity reached $836.6 million in Q4 2025 per NEO's latest filing, roughly flat from $838.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.1 billion in Q2 2021 to a low of $836.6 million in Q4 2025.
  • Average Common Equity over 5 years is $962.7 million, with a median of $944.5 million recorded in 2023.
  • Peak YoY movement for Common Equity: soared 75.53% in 2021, then fell 10.93% in 2022.
  • A 5-year view of Common Equity shows it stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Common Equity are $836.6 million (Q4 2025), $838.3 million (Q3 2025), and $854.0 million (Q2 2025).